Climb Bio, INC 10-Q quarterly reports

Climb Bio's Q2 2026 report highlights progress in budoprutug and CLYM116 development, alongside a substantial cash position, but underscores continued operational losses and future financing needs.

Climb Bio, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $13.7 million and a cash balance of $146.3 million, while advancing its key drug candidates.

Climb Bio, Inc. reported a net loss of $12.9 million for Q3 2025, while advancing its lead product candidates budoprutug and CLYM116 in clinical trials.

Climb Bio, a clinical-stage biotech, reported increased operating losses and significant R&D expenses in Q2 2025, driven by pipeline advancements, while maintaining a cash runway through 2027.

Climb Bio, a clinical-stage biotechnology company, announces its financial results for the first quarter of 2025, highlighting progress in its clinical development programs for immune-mediated diseases.

Climb Bio, formerly Eliem Therapeutics, reports its third quarter 2024 results, highlighting a strategic shift to immune-mediated diseases and progress in the development of its lead candidate, budoprutug.

Eliem Therapeutics reports a net loss of $54.9 million for the second quarter of 2024, which includes a significant expense related to the acquisition of Tenet Medicines.

Eliem Therapeutics will acquire Tenet Medicines in a merger and secure $120 million through a private placement to advance a clinical-stage autoimmune program.